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Abstract
Language impairment is common in prodromal stages of Alzheimer’s disease (AD) and progresses 
over time. However, the genetic architecture underlying language performance is poorly 
understood. To identify novel genetic variants associated with language performance, we analyzed 
brain MRI and performed a genome-wide association study (GWAS) using a composite measure 
of language performance from the Alzheimer’s Disease Neuroimaging Initiative (ADNI; n=1,560). 
The language composite score was associated with brain atrophy on MRI in language and 
semantic areas. GWAS identified GLI3 (GLI family zinc finger 3) as significantly associated with 
language performance (p < 5 × 10−8). Enrichment of GWAS association was identified in 
pathways related to nervous system development and glutamate receptor function and trafficking. 
Our results, which warrant further investigation in independent and larger cohorts, implicate GLI3, 
a developmental transcription factor involved in patterning brain structures, as a putative gene 
associated with language dysfunction in AD.
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1. Introduction
Alzheimer’s disease (AD), the most common neurodegenerative disorder, is clinically 
characterized by progressive cognitive impairment primarily in memory in the earliest 
stages. However, as the disease progresses, deficits can also be observed in other cognitive 
domains such as judgment, orientation, executive function, visuospatial ability, and 
language. Language impairment is a prevalent clinical feature that often occurs early on – 
sometimes even before AD is diagnosed, and progresses during the course of the disease 
(Ahmed, Haigh, de Jager, & Garrard, 2013). Several language tests have been shown to 
discriminate between cognitively normal (CN) and those with AD (Bertola et al., 2014; 
Clark et al., 2014; Gomez & White, 2006; Henry, Crawford, & Phillips, 2004). Hence, 
language impairment is one of several areas of cognitive decline that can aid in the clinical 
diagnosis of AD dementia according to the most recent criteria (McKhann et al., 2011). 
Language deficits during prodromal AD include impairments in word finding (Bayles, 
Tomoeda, & Trosset, 1990), naming (Hodges, Salmon, & Butters, 1991), and verbal fluency 
(Monsch et al., 1992; Nutter-Upham et al., 2008).
A large portion of the neuropsychological tests used to assess language impairment, such as 
the Boston Naming Test (BNT) and Animal Fluency, are dependent on semantic memory 
(Verma & Howard, 2012). It has been suggested that the language impairment observed in 
AD is primarily the result of a decline in semantic processing due to structural and 
organizational deterioration of semantic memory (Chertkow & Bub, 1990). Other memory 
systems affected include episodic memory, one of the earliest and most severely affected 
systems in AD (Hodges & Graham, 2001). Language impairments in prodromal and clinical 
AD have been previously associated with cortical atrophy predominantly in left temporal 
and parietal lobe regions, in addition to several other brain regions (Ahn et al., 2011; 
Apostolova et al., 2008; Domoto-Reilly, Sapolsky, Brickhouse, Dickerson, & Alzheimer's 
Disease Neuroimaging, 2012; Dos Santos et al., 2011). Similarly, there are functional 
changes on semantic fMRI tasks manifest early stage AD (Saykin et al., 1999). The genetic 
factors that contribute to different modalities of language function have also been 
investigated in adolescents and young adults with and without language disorders. For 
example, genome-wide association studies (GWAS) have identified candidate genes related 
to reading and language in adolescents to young adults (Gialluisi et al., 2014; Luciano et al., 
2013) and the morphology of Heschl’s gyrus in young adults (Cai et al., 2014). However, the 
genetic architecture underlying language performance in older adults with and at risk for AD 
has not been previously studied. To identify novel genetic variants specifically associated 
with language performance, we conducted a GWAS as well as a pathway-based analysis 
using the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort.
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2. Material and methods
2.1 Alzheimer’s disease neuroimaging initiative (ADNI)
The ADNI was launched in 2003 to help researchers and clinicians develop new treatments 
for mild cognitive impairment (MCI) and early AD dementia, monitor their effectiveness, 
and decrease the time and cost of clinical trials. One of ADNI’s major goals is to test 
whether serial magnetic resonance imaging (MRI) (Grundman et al.), positron emission 
tomography (PET), other biological markers, and clinical and neuropsychological 
assessment can be combined to measure the progression of MCI and AD. This multi-year 
multi-site longitudinal study was started by the National Institute on Aging (NIA), the 
National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Food and Drug 
Administration (FDA), private pharmaceutical companies, and non-profit organizations as a 
$60 million, 5-year public-private partnership. It was then extended for an additional 7 years 
through two additional phases of funding. The ADNI participants consist of AD dementia, 
MCI, and healthy elderly individuals with and without significant memory concern (i.e., 
SMC and CN, respectively). They were aged 55–90 years and recruited from 59 sites across 
the U.S. and Canada including medical and academic institutions. Further information can 
be found at http://www.adni-info.org/ and see (Aisen et al., 2010). The current study 
involved 1,575 subjects with genotyping: 370 CN, 94 SMC, 283 early MCI (EMCI), 515 
late MCI (LMCI), and 313 AD.
2.2 Phenotypes
A composite measure of language was generated as the target phenotype for this study using 
the following language measures from the ADNI neuropsychological test battery - the BNT, 
the Animal Fluency test, and the naming portion of AD Assessment Schedule-Cog (ADAS-
COG). Given the invariable presence of episodic memory deficits in the cognitively impaired 
ADNI population, we sought to capture language performance independent of episodic 
memory performance (Supplementary Table 1). Therefore, each language test (BNT, Animal 
Fluency, and ADAS-COG naming) was individually adjusted with a linear regression model 
for concomitant episodic memory deficits using a composite score for episodic memory 
(Crane et al., 2012) in IBM SPSS (version 22, Armonk, NY). The residuals were then used 
to generate a composite score using principal component analysis taking the resulting first 
component, which accounted for 66% of the variance, with the following loadings: animal 
fluency = 0.62, BNT = 0.84, and ADAS-COG naming = 0.76 (Supplementary Fig. 1). For 
each diagnostic group, a positive linear relationship was observed between each language 
measure with respect to episodic memory (Supplementary Table 2). Thus, diagnostic status 
was not considered in the derivation of the language composite score. This summary 
measure of language performance was used as the primary phenotype for GWAS. A total of 
1,560 subjects (365 CN, 94 SMC, 280 EMCI, 511 LMCI, 310 AD) had all three language 
test scores available for analyses. Age and sex were significantly associated (p<0.001; age, r 
= 0.15; sex, r = 0.11) with the generated language composite score pre-adjusted for episodic 
memory and were used as covariates in the following analyses.
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2.3 Structural MRI scans
Baseline 1.5T (ADNI-1) and 3T (ADNI-GO/2) magnetization-prepared rapid gradient-echo 
(MPRAGE) images were downloaded from the ADNI LONI site for all participants (http://
adni.loni.usc.edu/). Scan processing with voxel-based morphometry (VBM) in Statistical 
Parametric Mapping 8 (SPM8; Wellcome Trust Centre for Neuroimaging, http://
www.fil.ion.ucl.ac.uk/spm/software/spm8/) and quality control were done as previously 
described (Risacher et al., 2013). Overall, 71 subjects (17 CN, 5 SMC, 12 EMCI, 21 LMCI, 
16 AD) were excluded due to missing MRI scan data or failed processing, leaving 1,489 
subjects available for analyses. Analyses were performed separately for each magnetic field 
strength.
2.4 Genotyping and imputation
The Illumina610-Quad BeadChip was used for genotyping all ADNI-1 participants and the 
Illumina HumanOmni Express BeadChip or the Illumina Omni 2.5M was used for 
participants enrolled in ADNI-GO or ADNI-2 (Saykin et al., 2015). Un-genotyped single 
nucleotide polymorphisms (SNPs) were imputed as previously described (Nho et al., 2015). 
Since population stratification is known to cause spurious association in disease studies, 
from the ADNI participants, we restricted our analyses to only non-Hispanic Caucasian 
subjects that clustered with CEU (Utah residents with Northern and Western European 
ancestry from the CEPH collection) + TSI (Toscani in Italia) populations using HapMap 3 
genotype data and the multidimensional scaling (MDS) analysis (www.hapmap.org). 
Standard sample and SNP quality control procedures were then implemented; SNPs were 
excluded if the genotyping call rate was < 95%, Hardy-Weinberg equilibrium test p < 1 × 
10−6, sample call rate < 95%, or the minor allele frequency < 1%. In addition, sample sex 
marker mismatch check and DNA sample SNP fingerprint to microarray identity checks 
were also performed. MACH and 1000 Genomes Project data (build 37, hg19) as a reference 
panel were used for imputation. After quality control steps including filtering for MAF ≥ 5% 
on the imputed SNPs were applied, 1,575 of 1,716 ADNI participants and 5,574,300 SNPs 
remained for subsequent analyses.
2.5 Statistical analysis
A linear regression model in SPM8 using MRI scans was performed across voxels to 
evaluate the relationship of the language composite scores (unadjusted and pre-adjusted for 
episodic memory performance) with grey matter (GM) density. This enabled delineation of 
the regional associations between the language composite score and structural brain changes. 
Voxel-wise analysis was also used to determine the anatomical distribution of the association 
of the most significant SNP identified in the GWAS (see section below) with GM density. 
Voxel-wise analyses included age, sex, years of education, intracranial volume, and 
apolipoprotein E (APOE) ε4 status as covariates. Language abilities are typically lateralized 
to the left hemisphere, however some left handed individuals show right hemisphere or 
mixed dominance and thus handedness was also included as a covariate (Knecht et al., 
2000). Significant results were displayed with a minimum cluster size (k;(Friston, Holmes, 
Worsley, Poline, & Frackowiak, 1995) of 100 contiguous voxels and a voxel-wise threshold 
of p < 0.001 (both uncorrected and corrected for multiple comparisons). Anatomical regions 
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were defined using the x-y-z coordinates for the most significant voxel within each cluster. 
These coordinates were entered into the Talairach daemon (http://www.talairach.org/
daemon.html) to receive the anatomical names for the GM regions closest to that coordinate 
(Lancaster et al., 2000).
A GWAS across the whole sample (n=1560) was performed using a linear regression under 
an additive genetic model in PLINK (Purcell et al., 2007) with the language composite pre-
adjusted for episodic memory performance as the endophenotype to specifically target 
language-specific cognitive function in a population with known memory impairment (Rabin 
et al., 2009). Age, sex, handedness, years of education, APOE ε4 status, and genotyping 
platform were used as covariates. Bonferroni method was applied for correcting for multiple 
comparisons and SNPs with p < 5 × 10−8 were considered genome-wide significant (Pe'er, 
Yelensky, Altshuler, & Daly, 2008). Permutation testing (109 permutations) of the most 
significant SNP was implemented in PLINK to ensure that the language composite measure 
had did not deviate from normal distribution. Manhattan and Quantile-Quantile plots were 
generated in R using the ‘qqman’ package and regional association plots were generated 
with LocusZoom (Pruim et al., 2010). Linkage disequilibrium (LD) was estimated and 
visualized with D' using haploview (http://www.broad.mit.edu/mpg/haploview). The p-
values obtained from the GWAS results and the GSA-SNP software (Nam, Kim, Kim, & 
Kim, 2010) were then utilized to identify pathways enriched with SNPs showing association 
to language performance (Ramanan, Kim, et al., 2012). We restricted downstream analysis 
to pathways containing 5–100 genes and used false discovery rate (FDR) to correct for 
pathway-level multiple comparisons. Pathway definitions were downloaded from the 
Molecular Signatures Database (http://www.broadinstitute.org/gsea/msigdb/index.jsp; 
canonical pathways set, version 4.0).
3. Results
Sample characteristics of the participants used in this study are presented in Table 1. To 
assess brain regions in which grey matter (GM) density is associated with the generated 
language composite score pre-adjusted for episodic memory, we used VBM. A significant 
association between poorer language performance, both adjusted and unadjusted for episodic 
memory performance, and reduced GM density throughout the brain was observed (Fig. 1 
and supplemental Fig. 2–3). Specifically, worse performance on the unadjusted score was 
associated with reduced GM density in nearly the entire cortex (Supplemental Fig. 2). 
However, performance on the language composite pre-adjusted for episodic memory 
performance showed a more localized pattern of association, with poorer performance 
associated with reduced GM density in the middle and superior temporal gyrus (Brodmann 
area (BA) 21 and BA22), predominantly lateralized to the left hemisphere (Fig. 1 and 
supplemental Fig. 3). We observed a larger region significantly associated with language 
performance in ADNI-GO/2, likely due to the increased sensitivity of the 3T scans to 
degeneration.
A GWAS was performed to identify genetic variants that might influence language 
performance using the language composite score pre-adjusted for episodic memory as the 
phenotype. GWAS identified four SNPs (rs3801203, p = 3.21 × 10−9; rs3779159, p = 7.12 × 
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10−9; rs3801206, p = 6.13 × 10−9; and rs74745318, p = 7.12 × 10−9; supplemental Table 1) 
in the region of GLI3 (GLI family zinc finger 3) that displayed genome-wide significant 
association with language function (Fig. 2a–b). The genomic inflation factor (λ) was 1.026 
indicating no evidence for bias or inflation of our test statistics due to population 
stratification (Fig. 2c). These SNPs are intronic and demonstrated strong LD (Fig. 3a). To 
ensure our composite score had a normal distribution, permutation testing of the most 
significant SNP, rs3801203, resulted in the same p-value of 3.21 × 10−9 suggesting our 
phenotype had a normal distribution. Each SNP was also tested with BNT, ADAS-COG 
naming, and animal fluency, individually. All four GLI3 SNPs were significantly associated 
with BNT and ADAS-COG naming (p< 1 × 10−5). The minor allele of each SNP (data not 
shown) including rs3801203, was associated with worse language performance across all 
subjects (Fig. 3b) and diagnostic groups with the exception of the smallest group, SMC (Fig. 
3c). An additional 31 SNPs in five additional genes displayed suggestive association (p < 5 × 
10− 6) for language performance (Supplemental Table 3).
The four SNPs identified in the GWAS are in high LD thus we chose the most significant 
SNP, rs3801203, to determine if the genetic variants associated with language performance 
were also associated with GM density. GLI3 SNP rs3801203 was associated with lower GM 
density in both the ADNI-1 and ADNI-GO/2 cohorts (Fig. 4). Specifically, in the ADNI-1 
cohort, the minor allele of rs3801203 was associated with atrophy in the middle and superior 
temporal gyrus (BA 21 and BA22, respectively; Fig. 4a), amongst other regions such as the 
fusiform, cingulate gyrus, and precuneus (Supplemental Table 4). However, in the ADNI-
GO/2 cohort, the minor allele of rs3801203 was only found to be associated with atrophy in 
the inferior frontal gyrus (orbitofrontal cortex; Fig. 4b).
Pathway- enrichment analysis identified 24 pathways associated (FDR p < 0.01) with 
language performance. The top 20 pathways are presented in Table 2 and include pathways 
related to nervous system development, such as neuronal migration, axon guidance, and cell 
differentiation. Additional pathways included glutamate receptor trafficking and function, 
immune activation, apoptosis, and others.
4. Discussion
We generated a language composite score using measures from animal fluency, BNT, and 
ADAS-COG naming. In the ADNI sample, MRI analysis identified significant GM atrophy 
across the whole-brain in relation to the language composite score unadjusted for episodic 
memory. However, GM atrophy in the left temporal, parietal, and frontal lobes were 
significantly associated with language performance pre-adjusted for episodic memory. These 
brain regions have previously been implicated in language and semantic memory processes 
(Apostolova et al., 2008; Domoto-Reilly et al., 2012; Joubert et al., 2010; McDonald, Bean, 
& Saykin, 2011; Saykin et al., 1999). We then investigated the effect of genetic variations on 
this language composite score using GWAS and pathway-enrichment analysis techniques in 
individuals at risk for and with AD from the ADNI cohort. GWAS identified variants in 
GLI3 significantly associated with language impairment. Genetic variation in GLI3 was also 
associated with lower GM density predominantly in the temporal lobes. Finally, neuronal 
development, glutamate receptor trafficking, immune function, and apoptotic pathways 
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showed enriched associated with language performance in this sample. To our knowledge, 
this study is the first to identify GLI3 variation as associated with language performance.
GLI3 encodes one of three GLI zinc finger transcription factors expressed early in 
development that is normally involved in patterning brain structures (Blaess, Corrales, & 
Joyner, 2006; Ruppert, Vogelstein, Arheden, & Kinzler, 1990). The GLI3 protein is an 
important downstream mediator of the Sonic Hedgehog pathway and can act as an activator 
or repressor in the presence or absence of Sonic Hedgehog, respectively (Wang, Fallon, & 
Beachy, 2000). Mutations to this pathway are causative for developmental disorders which 
affect the limbs, head, and face (Kalff-Suske et al., 1999; Kang, Graham, Olney, & 
Biesecker, 1997).
GLI3 may also have a more direct role in development of the corpus callosum (Amaniti et 
al., 2013; Magnani et al., 2014) and hippocampus (Hasenpusch-Theil et al., 2012; Palma & 
Ruiz i Altaba, 2004). One study showed GLI3 expression was downregulated in the presence 
of Presenilin 1 (PSEN1), a protein which forms part of the γ-secretase complex involved in 
amyloid-beta production, ultimately leading to decreased neuronal differentiation (Paganelli 
et al., 2001). Notably, mutations in the PSEN1 gene are causative for some forms of early-
onset autosomal dominant AD, including mutations with an aphasic phenotype (Denvir et 
al., 2015). Another study showed GLI3 expression is capable of repressing Pitrm1 (pitrilysin 
metallopeptidase) using limb tissue from GLI3 mutant mice (Town et al., 2009). The Pitrm1 
protein is a metalloendopeptidase which is able to degrade amyloid-beta when it 
accumulates in mitochondria (Falkevall et al., 2006). Further Pitrm1 has been shown to have 
decreased expression in the temporal lobe of AD subjects (Alikhani et al., 2011), as well as 
decreased antisense expression in AD subjects compared to controls (Sekar et al., 2015). In 
light of these studies, our observed findings may suggest that this system could be 
dysregulated in older adults at risk for AD. Future studies exploring the relationships 
between GLI3, PSEN1, and Pitrm1 within the brain and in the context of AD would help to 
elucidate any potential role of this system in AD etiology.
To date, the four GLI3 SNPs identified in this study have not been linked to any other 
biological pathway or pathology to our knowledge. We found that these genetic variants 
were independently associated with BNT and ADAS-COG naming, but not with animal 
fluency, suggesting the language composite score was more reflective of naming rather than 
fluency. Furthermore, the minor allele of rs3801203 in the ADNI-1 cohort was associated 
with atrophy in brain regions associated with auditory processing. However, this finding did 
not replicate in the ADNI-GO/2 cohort which could be due to differences in scanner 
strength. This could also be due to the sample characteristics of these two cohorts. The 
ADNI-1 cohort includes mainly subjects who are later in the disease course and ADNI-GO/2 
includes predominantly subjects that are earlier in the disease course. This could account for 
the larger variation in atrophy in relation to the language composite score seen in ADNI-
GO/2. Moreover, the effect of rs3801203 may occur later in the disease course which could 
account for why more atrophy is observed in the ADNI-1 cohort.
Pathway-based analysis has provided useful insights into the underlying biological processes 
of complex genetic diseases by integrating and assessing the contribution of multiple genes 
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and proteins across an intricate network of pathways and subnetworks (Ramanan, Shen, 
Moore, & Saykin, 2012). This pathway analysis identified several associations between 
nervous system development pathways and language performance. Specifically, one domain 
identified in the pathway analysis was glutamate receptor function and trafficking pathways. 
Glutamate is the primary excitatory neurotransmitter in the brain and is implicated in AD 
pathophysiology and neuronal cell death. Glutamate receptors have been under investigation 
as a therapeutic target for AD and other neurological disorders (Caraci et al., 2011; Morin et 
al., 2013; Olivares et al., 2012; Rosini, Simoni, Minarini, & Melchiorre, 2014). Memantine, 
a weak N-Methyl-D-aspartate channel blocker, has shown efficacy in reducing clinical 
decline in moderate AD and is widely used clinically (Reisberg et al., 2003; Tariot et al., 
2004). Our results suggest that alterations in glutamate neurotransmission or receptor 
trafficking may play a critical role in language performance and functional semantic 
memory in AD.
One notable limitation of this study is the lack of a similar cohort to replicate our findings. 
Future studies investigating GLI3 in independent cohorts with similar neuroimaging and 
cognitive assessments should be done to confirm our results. In addition, further 
investigations about the functional impact of the observed significant GLI3 SNPs on a 
cellular or molecular level are warranted. Causal directions are yet to be determined but 
future studies may be able to capture the complicated relationship between the genetic, 
neuroimaging, and language domains using advanced statistical modeling such as mediation 
analysis or structural equation modeling. In view of the previously identified association of 
GLI3 with an amyloid-related protein (e.g.,PSEN1) as described above, future studies 
should also focus on evaluating the impact of GLI3 variation on amyloid phenotypes in older 
adults at risk for AD.
To our knowledge, this is the first reported GWAS of language performance in older adults 
at risk for or with AD. Our results identified novel associations of GLI3, a developmental 
transcription factor involved in patterning brain structures, with language dysfunction. 
Further, pathway analysis identified neuronal development and glutamate receptor pathways 
as enriched. Future studies will help to fully elucidate the underlying biology and 
importance of GLI3 and identified pathways in AD etiology and/or their potential as 
therapeutic targets.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Data collection and sharing was funded by the ADNI (National Institutes of Health Grant U01 AG024904) and 
DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National 
Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous 
contributions from the following: Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; BioClinica, 
Inc.; Biogen Idec Inc.; Bristol- Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and 
Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, 
N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson 
Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; 
NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and 
Deters et al. Page 8
Brain Lang. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI 
clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of 
Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and 
Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of 
California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of 
Southern California.
The specific analyses reported here were supported in part by grants from the NIH including P30 AG10133, R01 
AG19771, R01 LM011360, R01 AG040770, R01 AG042437, and R00 LM011384, K02 AG048240, as well the 
Alzheimer’s Association, Indiana CTSI (NIH grants U54 RR025761, RR027710-01, and RR020128), NIA grants 
R36 AG053445 and KO1 AG049050, and NSF grant IIS-1117335.
References
Ahmed S, Haigh AM, de Jager CA, Garrard P. Connected speech as a marker of disease progression in 
autopsy-proven Alzheimer's disease. Brain. 2013; 136(Pt 12):3727–3737. DOI: 10.1093/brain/
awt269 [PubMed: 24142144] 
Ahn HJ, Seo SW, Chin J, Suh MK, Lee BH, Kim ST, Na DL. The cortical neuroanatomy of 
neuropsychological deficits in mild cognitive impairment and Alzheimer's disease: a surface-based 
morphometric analysis. Neuropsychologia. 2011; 49(14):3931–3945. DOI: 10.1016/
j.neuropsychologia.2011.10.010 [PubMed: 22019776] 
Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG. Alzheimer's Disease 
Neuroimaging, I. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and 
plans. Alzheimers Dement. 2010; 6(3):239–246. DOI: 10.1016/j.jalz.2010.03.006 [PubMed: 
20451872] 
Alikhani N, Guo L, Yan S, Du H, Pinho CM, Chen JX, Yan SS. Decreased proteolytic activity of the 
mitochondrial amyloid-beta degrading enzyme, PreP peptidasome, in Alzheimer's disease brain 
mitochondria. J Alzheimers Dis. 2011; 27(1):75–87. DOI: 10.3233/JAD-2011-101716 [PubMed: 
21750375] 
Amaniti EM, Hasenpusch-Theil K, Li Z, Magnani D, Kessaris N, Mason JO, Theil T. Gli3 is required 
in Emx1+ progenitors for the development of the corpus callosum. Dev Biol. 2013; 376(2):113–124. 
DOI: 10.1016/j.ydbio.2013.02.001 [PubMed: 23396189] 
Apostolova LG, Lu P, Rogers S, Dutton RA, Hayashi KM, Toga AW, Thompson PM. 3D mapping of 
language networks in clinical and pre-clinical Alzheimer's disease. Brain Lang. 2008; 104(1):33–41. 
DOI: 10.1016/j.bandl.2007.03.008 [PubMed: 17485107] 
Bayles KA, Tomoeda CK, Trosset MW. Naming and categorical knowledge in Alzheimer's disease: the 
process of semantic memory deterioration. Brain Lang. 1990; 39(4):498–510. [PubMed: 2076493] 
Bertola L, Mota NB, Copelli M, Rivero T, Diniz BS, Romano-Silva MA, Malloy-Diniz LF. Graph 
analysis of verbal fluency test discriminate between patients with Alzheimer's disease, mild 
cognitive impairment and normal elderly controls. Front Aging Neurosci. 2014; 6:185.doi: 10.3389/
fnagi.2014.00185 [PubMed: 25120480] 
Blaess S, Corrales JD, Joyner AL. Sonic hedgehog regulates Gli activator and repressor functions with 
spatial and temporal precision in the mid/hindbrain region. Development. 2006; 133(9):1799–1809. 
DOI: 10.1242/dev.02339 [PubMed: 16571630] 
Cai DC, Fonteijn H, Guadalupe T, Zwiers M, Wittfeld K, Teumer A, Hagoort P. A genome-wide search 
for quantitative trait loci affecting the cortical surface area and thickness of Heschl's gyrus. Genes 
Brain Behav. 2014; 13(7):675–685. DOI: 10.1111/gbb.12157 [PubMed: 25130324] 
Caraci F, Molinaro G, Battaglia G, Giuffrida ML, Riozzi B, Traficante A, Nicoletti F. Targeting group 
II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with 
Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in 
cultured neurons, whereas dual activation of mGlu2 and mGlu3 receptors is neuroprotective. Mol 
Pharmacol. 2011; 79(3):618–626. DOI: 10.1124/mol.110.067488 [PubMed: 21159998] 
Chertkow H, Bub D. Semantic memory loss in dementia of Alzheimer's type. What do various 
measures measure? Brain. 1990; 113(Pt 2):397–417. [PubMed: 2328410] 
Deters et al. Page 9
Brain Lang. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Clark DG, Kapur P, Geldmacher DS, Brockington JC, Harrell L, DeRamus TP, Marson DC. Latent 
information in fluency lists predicts functional decline in persons at risk for Alzheimer disease. 
Cortex. 2014; 55:202–218. DOI: 10.1016/j.cortex.2013.12.013 [PubMed: 24556551] 
Crane PK, Carle A, Gibbons LE, Insel P, Mackin RS, Gross A. Alzheimer's Disease Neuroimaging, I. 
Development and assessment of a composite score for memory in the Alzheimer's Disease 
Neuroimaging Initiative (ADNI). Brain Imaging Behav. 2012; 6(4):502–516. DOI: 10.1007/
s11682-012-9186-z [PubMed: 22782295] 
Denvir J, Neitch S, Fan J, Niles RM, Boskovic G, Schreurs BG, Alkon DL. Identification of the PS1 
Thr147Ile Variant in a Family with Very Early Onset Dementia and Expressive Aphasia. J 
Alzheimers Dis. 2015; doi: 10.3233/JAD-150051
Domoto-Reilly K, Sapolsky D, Brickhouse M, Dickerson BC. Alzheimer's Disease Neuroimaging, I. 
Naming impairment in Alzheimer's disease is associated with left anterior temporal lobe atrophy. 
Neuroimage. 2012; 63(1):348–355. DOI: 10.1016/j.neuroimage.2012.06.018 [PubMed: 22728617] 
Dos Santos V, Thomann PA, Wustenberg T, Seidl U, Essig M, Schroder J. Morphological cerebral 
correlates of CERAD test performance in mild cognitive impairment and Alzheimer's disease. J 
Alzheimers Dis. 2011; 23(3):411–420. DOI: 10.3233/JAD-2010-100156 [PubMed: 21116054] 
Falkevall A, Alikhani N, Bhushan S, Pavlov PF, Busch K, Johnson KA, Glaser E. Degradation of the 
amyloid beta-protein by the novel mitochondrial peptidasome, PreP. J Biol Chem. 2006; 281(39):
29096–29104. DOI: 10.1074/jbc.M602532200 [PubMed: 16849325] 
Friston K, Holmes A, Worsley K, Poline J-B, Frackowiak R. Statistical parametric maps in functional 
imaging: a general linear approach. Hum Brain Mapp. 1995; 2:189–210.
Gialluisi A, Newbury DF, Wilcutt EG, Olson RK, DeFries JC, Brandler WM, Fisher SE. Genome-wide 
screening for DNA variants associated with reading and language traits. Genes Brain Behav. 2014; 
13(7):686–701. DOI: 10.1111/gbb.12158 [PubMed: 25065397] 
Gomez RG, White DA. Using verbal fluency to detect very mild dementia of the Alzheimer type. Arch 
Clin Neuropsychol. 2006; 21(8):771–775. DOI: 10.1016/j.acn.2006.06.012 [PubMed: 17011743] 
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA. Alzheimer's Disease 
Cooperative, S. Mild cognitive impairment can be distinguished from Alzheimer disease and 
normal aging for clinical trials. Arch Neurol. 2004; 61(1):59–66. DOI: 10.1001/archneur.61.1.59 
[PubMed: 14732621] 
Hasenpusch-Theil K, Magnani D, Amaniti EM, Han L, Armstrong D, Theil T. Transcriptional analysis 
of Gli3 mutants identifies Wnt target genes in the developing hippocampus. Cereb Cortex. 2012; 
22(12):2878–2893. DOI: 10.1093/cercor/bhr365 [PubMed: 22235033] 
Henry JD, Crawford JR, Phillips LH. Verbal fluency performance in dementia of the Alzheimer's type: 
a meta-analysis. Neuropsychologia. 2004; 42(9):1212–1222. DOI: 10.1016/j.neuropsychologia.
2004.02.001 [PubMed: 15178173] 
Hodges JR, Graham KS. Episodic memory: insights from semantic dementia. Philos Trans R Soc Lond 
B Biol Sci. 2001; 356(1413):1423–1434. DOI: 10.1098/rstb.2001.0943 [PubMed: 11571033] 
Hodges JR, Salmon DP, Butters N. The nature of the naming deficit in Alzheimer's and Huntington's 
disease. Brain. 1991; 114(Pt 4):1547–1558. [PubMed: 1832072] 
Joubert S, Brambati SM, Ansado J, Barbeau EJ, Felician O, Didic M, Kergoat MJ. The cognitive and 
neural expression of semantic memory impairment in mild cognitive impairment and early 
Alzheimer's disease. Neuropsychologia. 2010; 48(4):978–988. DOI: 10.1016/j.neuropsychologia.
2009.11.019 [PubMed: 19954747] 
Kalff-Suske M, Wild A, Topp J, Wessling M, Jacobsen EM, Bornholdt D, Grzeschik KH. Point 
mutations throughout the GLI3 gene cause Greig cephalopolysyndactyly syndrome. Hum Mol 
Genet. 1999; 8(9):1769–1777. [PubMed: 10441342] 
Kang S, Graham JM Jr, Olney AH, Biesecker LG. GLI3 frameshift mutations cause autosomal 
dominant Pallister-Hall syndrome. Nat Genet. 1997; 15(3):266–268. DOI: 10.1038/ng0397-266 
[PubMed: 9054938] 
Knecht S, Drager B, Deppe M, Bobe L, Lohmann H, Floel A, Henningsen H. Handedness and 
hemispheric language dominance in healthy humans. Brain. 2000; 123(Pt 12):2512–2518. 
[PubMed: 11099452] 
Deters et al. Page 10
Brain Lang. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, Fox PT. Automated 
Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000; 10(3):120–131. 
[PubMed: 10912591] 
Luciano M, Evans DM, Hansell NK, Medland SE, Montgomery GW, Martin NG, Bates TC. A 
genome-wide association study for reading and language abilities in two population cohorts. 
Genes Brain Behav. 2013; 12(6):645–652. DOI: 10.1111/gbb.12053 [PubMed: 23738518] 
Magnani D, Hasenpusch-Theil K, Benadiba C, Yu T, Basson MA, Price DJ, Theil T. Gli3 controls 
corpus callosum formation by positioning midline guideposts during telencephalic patterning. 
Cereb Cortex. 2014; 24(1):186–198. DOI: 10.1093/cercor/bhs303 [PubMed: 23042737] 
McDonald, BC., Bean, J., Saykin, AJ. fMRI Wada test: Prospects for presurgical mapping of language 
and memory. In: Faro, SH., Mohamed, FB., editors. Functional Neuroradiology: Principles and 
Clinical Applications. Springer; 2011. 
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Phelps CH. The 
diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on 
Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. 
Alzheimers Dement. 2011; 7(3):263–269. DOI: 10.1016/j.jalz.2011.03.005 [PubMed: 21514250] 
Monsch AU, Bondi MW, Butters N, Salmon DP, Katzman R, Thal LJ. Comparisons of verbal fluency 
tasks in the detection of dementia of the Alzheimer type. Arch Neurol. 1992; 49(12):1253–1258. 
[PubMed: 1449404] 
Morin N, Gregoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T. MPEP, 
an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications 
in de novo parkinsonian monkeys: biochemical correlates. Neuropharmacology. 2013; 66:355–
364. DOI: 10.1016/j.neuropharm.2012.07.036 [PubMed: 22884464] 
Nam D, Kim J, Kim SY, Kim S. GSA-SNP: a general approach for gene set analysis of 
polymorphisms. Nucleic Acids Res. 2010; 38(Web Server issue):W749–754. DOI: 10.1093/nar/
gkq428 [PubMed: 20501604] 
Nho K, Ramanan VK, Horgusluoglu E, Kim S, Inlow MH, Risacher SL, Saykin AJ. Comprehensive 
Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults. J Alzheimers Dis. 
2015; doi: 10.3233/JAD-148009
Nutter-Upham KE, Saykin AJ, Rabin LA, Roth RM, Wishart HA, Pare N, Flashman LA. Verbal 
fluency performance in amnestic MCI and older adults with cognitive complaints. Arch Clin 
Neuropsychol. 2008; 23(3):229–241. DOI: 10.1016/j.acn.2008.01.005 [PubMed: 18339515] 
Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X. N-methyl D-aspartate 
(NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular 
dementia and Parkinson's disease. Curr Alzheimer Res. 2012; 9(6):746–758. [PubMed: 21875407] 
Paganelli AR, Ocana OH, Prat MI, Franco PG, Lopez SL, Morelli L, Carrasco AE. The Alzheimer-
related gene presenilin-1 facilitates sonic hedgehog expression in Xenopus primary neurogenesis. 
Mech Dev. 2001; 107(1-2):119–131. [PubMed: 11520668] 
Palma V, Ruiz i Altaba A. Hedgehog-GLI signaling regulates the behavior of cells with stem cell 
properties in the developing neocortex. Development. 2004; 131(2):337–345. DOI: 10.1242/dev.
00930 [PubMed: 14681189] 
Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide 
association studies of nearly all common variants. Genet Epidemiol. 2008; 32(4):381–385. DOI: 
10.1002/gepi.20303 [PubMed: 18348202] 
Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Willer CJ. LocusZoom: regional 
visualization of genome-wide association scan results. Bioinformatics. 2010; 26(18):2336–2337. 
DOI: 10.1093/bioinformatics/btq419 [PubMed: 20634204] 
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Sham PC. PLINK: a tool set 
for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 
81(3):559–575. DOI: 10.1086/519795 [PubMed: 17701901] 
Rabin LA, Saykin AJ, West JD, Borgos MJ, Wishart HA, Nutter-Upham KE, Santulli RB. Judgment in 
Older Adults with Normal Cognition, Cognitive Complaints, MCI, and Mild AD: Relation to 
Regional Frontal Gray Matter. Brain Imaging Behav. 2009; 3(2):212–219. DOI: 10.1007/
s11682-009-9063-6 [PubMed: 24741381] 
Deters et al. Page 11
Brain Lang. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL. Alzheimer's Disease Neuroimaging, I. 
Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging 
Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain 
Imaging Behav. 2012; 6(4):634–648. DOI: 10.1007/s11682-012-9196-x [PubMed: 22865056] 
Ramanan VK, Shen L, Moore JH, Saykin AJ. Pathway analysis of genomic data: concepts, methods, 
and prospects for future development. Trends Genet. 2012; 28(7):323–332. DOI: 10.1016/j.tig.
2012.03.004 [PubMed: 22480918] 
Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, Memantine Study G. Memantine in 
moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348(14):1333–1341. DOI: 10.1056/
NEJMoa013128 [PubMed: 12672860] 
Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC. Alzheimer's Disease Neuroimaging 
Initiative, d. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-
MCI). Front Aging Neurosci. 2013; 5:11.doi: 10.3389/fnagi.2013.00011 [PubMed: 23554593] 
Rosini M, Simoni E, Minarini A, Melchiorre C. Multi-target design strategies in the context of 
Alzheimer's disease: acetylcholinesterase inhibition and NMDA receptor antagonism as the driving 
forces. Neurochem Res. 2014; 39(10):1914–1923. DOI: 10.1007/s11064-014-1250-1 [PubMed: 
24493627] 
Ruppert JM, Vogelstein B, Arheden K, Kinzler KW. GLI3 encodes a 190-kilodalton protein with 
multiple regions of GLI similarity. Mol Cell Biol. 1990; 10(10):5408–5415. [PubMed: 2118997] 
Saykin AJ, Flashman LA, Frutiger SA, Johnson SC, Mamourian AC, Moritz CH, Weaver JB. 
Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of 
functional MRI activation. J Int Neuropsychol Soc. 1999; 5(5):377–392. [PubMed: 10439584] 
Saykin AJ, Shen L, Yao X, Kim S, Nho K, Risacher SL. Alzheimer's Disease Neuroimaging, I. 
Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and 
plans. Alzheimers Dement. 2015; 11(7):792–814. DOI: 10.1016/j.jalz.2015.05.009 [PubMed: 
26194313] 
Sekar S, McDonald J, Cuyugan L, Aldrich J, Kurdoglu A, Adkins J, Liang WS. Alzheimer's disease is 
associated with altered expression of genes involved in immune response and mitochondrial 
processes in astrocytes. Neurobiol Aging. 2015; 36(2):583–591. DOI: 10.1016/j.neurobiolaging.
2014.09.027 [PubMed: 25448601] 
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study G. 
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving 
donepezil: a randomized controlled trial. JAMA. 2004; 291(3):317–324. DOI: 10.1001/jama.
291.3.317 [PubMed: 14734594] 
Town L, McGlinn E, Fiorenza S, Metzis V, Butterfield NC, Richman JM, Wicking C. The 
metalloendopeptidase gene Pitrm1 is regulated by hedgehog signaling in the developing mouse 
limb and is expressed in muscle progenitors. Dev Dyn. 2009; 238(12):3175–3184. DOI: 10.1002/
dvdy.22126 [PubMed: 19877269] 
Verma M, Howard RJ. Semantic memory and language dysfunction in early Alzheimer's disease: a 
review. Int J Geriatr Psychiatry. 2012; 27(12):1209–1217. DOI: 10.1002/gps.3766 [PubMed: 
22298328] 
Wang B, Fallon JF, Beachy PA. Hedgehog-regulated processing of Gli3 produces an anterior/posterior 
repressor gradient in the developing vertebrate limb. Cell. 2000; 100(4):423–434. [PubMed: 
10693759] 
Deters et al. Page 12
Brain Lang. Author manuscript; available in PMC 2018 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
• We identified novel genetic variants associated with language performance.
• Minor allele variants in GLI3 are associated with worse language 
performance.
• Anatomical changes in language regions associated with language composite 
score.
• Developmental and glutamate pathways were related to lower language 
performance.
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Figure 1. 
Global regions associated with the language composite score pre-adjusted for episodic 
memory performance in ADNI participants. Grey matter density was positively correlated 
with the language composite score in the temporal lobe and language areas for both ADNI-1 
(a) and ADNI-GO/2 (b). Covariates included age, sex, intracranial volume, APOE ε4 status, 
and handedness. Results are displayed at p<0.001 (uncorrected) and at a threshold (k) of 100 
voxels.
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Figure 2. 
Manhattan, regional association, and quantile-quantile plots for GWAS of language 
performance. (a) Observed –log10 p-values (y-axis) are displayed for all tested SNPs on each 
chromosome (x-axis). A SNP was considered genome-wide significant if p < 5 × 10−8 
(above red line). Suggestive SNP associations were identified as those reaching genome-
wide significance of p < 1 × 10−5 (above blue line). (b) Regional association plot showing 
the region around the most significant SNP in the GWAS. The SNPs within 500 kb of 
rs3801203 are plotted as their GWAS −log10 P-values against their NCBI 37 genomic 
position. The blue line indicates recombination rates estimated from the 1000 Genomes 
Project reference data. The color scale of r2 values is used to label SNPs based on their 
correlation with rs3801203. (c) The genomic inflation factor (λ) was 1.026 suggesting no 
population stratification effect.
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Figure 3. 
GLI3 SNPs are associated with lower language performance. (a) Linkage disequilibrium 
map of the four GLI3 SNPs significantly associated with language performance. The minor 
allele of rs3801203 (b-c, p = 3.21 × 10−9) was associated with lower language composite 
score in older adults at risk for or with AD, with the exception of the SMC group. Means 
adjusted for age, sex, years of education, genotyping platform, handedness, and APOE ε4 
status. Standard errors are displayed.
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CN = cognitively normal; SMC = significant memory concern; EMCI = early mild cognitive 
impairment; LMCI = late mild cognitive impairment; AD = Alzheimer’s disease
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Figure 4. 
The minor allele of GLI3 SNP rs3801203 is associated with lower grey matter density in the 
temporal cortex of ADNI-1 participants (a) and the orbitofrontal cortex for ADNI-GO/2 
participants (b). Covariates included age, sex, intracranial volume, APOE ε4 status, and 
handedness. Results are displayed at p<0.001 (uncorrected) and at a threshold (k) of 100 
voxels.
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Table 2
Top 20 pathways associated with language performance.
Pathway description (Source database) Sizea Uncorrected pb
Netrin-1 signaling (Reactome) 36 2.38E-07
L1CAM interactions (Reactome) 76 9.39E-07
Arrythmogenic right ventricular cardiomyopathy (KEGG) 71 9.78E-07
Ion channel transport (Reactome) 48 5.33E-06
SHH pathway (Biocarta) 15 6.81E-06
Phosphatidylinositol signaling system (KEGG) 75 9.84E-06
Trafficking of AMPA receptors (Reactome) 26 1.17E-05
NRAGE signals death through JNK (Reactome) 37 1.39E-05
Adherens junction (KEGG) 71 1.39E-05
Synthesis of PIPs at the plasma membrane (Reactome) 28 1.59E-05
Integrin cell surface reactions (Reactome) 74 1.72E-05
FC gamma R-mediated phagocytosis (KEGG) 90 4.91E-05
ECM-receptor interaction (KEGG) 81 5.64E-05
Cell death signaling via NGRAGE, NRIF, and NADE (Reactome) 51 7.69E-05
Semaphorin interactions (Reactome) 61 9.89E-05
Hypertrophic cardiomyopathy-HCM (KEGG) 79 1.15E-04
Unblocking of NMDA receptor glutamate binding and activation (Reactome) 14 1.53E-04
Interaction between L1 and Ankyrins (Reactome) 20 1.57E-04
PI metabolism (Reactome) 44 1.59E-04
Glioma (KEGG) 63 1.73E-04
aNumber of genes in the pathway.
bAll pathway displayed are significant at false discovery rate (FDR)-corrected p < 0.01.
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